RevenanasBook a free audit

Layoffs

Ultragenyx lays off 20% of workforce and axes drug programs to halve R&D spend

Biotech

Layoffs

Key Facts

Signal Type

Layoffs

Industry

Biotech

Companies

Ultragenyx

Date

What Happened

Ultragenyx announced a 20% workforce reduction (approximately 370 employees) after market close on Tuesday, aiming to cut its annual R&D budget in half by 2027. The biopharma is winding down all studies of GTX-102 (Angelman syndrome) following a failed Phase 3 trial and ending development of UX701 (Wilson disease) due to lackluster data. CEO Emil Kakkis stated the company will shift resources from early-stage R&D to growing sales of its six commercial products, with most of the proposed $350 million 2027 R&D budget earmarked for commercial programs, monitoring, and regulatory filings.

Who Is Affected

The layoffs primarily impact R&D staff, as Ultragenyx reduces its workforce from 1,371 to approximately 1,000 employees. The company is also shrinking its real estate footprint as part of cost-containment. The two discontinued programs—GTX-102 and UX701—will see all ongoing studies wound down, affecting patients and partners involved in those trials. Remaining pipeline programs include DTX301 (Phase 3 for OTC deficiency) and setrusumab (antibody for osteogenesis imperfecta), though the latter faces regulatory hurdles after two Phase 3 failures.

Market Impact

  • Commercial ops & CRM: With Ultragenyx pivoting to commercial sales of six products, vendors of sales enablement, CRM, and revenue intelligence platforms have a clear entry point.
  • Facilities & IT rationalization: The real estate reduction creates opportunities for facilities management, IT infrastructure consolidation, and remote-work enablement solutions.
  • Deal-sourcing & BD intelligence: Kakkis signaled openness to small, high-value licensing deals, making deal-sourcing platforms and biotech M&A intelligence tools relevant.
  • R&D cost management: The drive to halve R&D spend suggests demand for cost-efficient CROs, lab software, and portfolio management tools.

What to Watch

Monitor Ultragenyx’s progress toward profitability in 2027, including any new licensing deals or partnerships that align with its “small, smart deals” strategy. The fate of setrusumab and DTX301 will be key pipeline milestones. Additionally, watch for further real estate dispositions and any follow-on layoffs as the company completes the restructuring this year.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner